News & insights

Thoughts

Making the most of AFA submissions via the EUIPO’s new IPEP system

Counterfeit goods are on the rise across Europe, and the most effective way to stop them is before they reach the market, at the border. The European Union Intellectual Property Office (EUIPO) has rec...

Thoughts

Hijacking natural pathways: Targeted protein degradation

Targeted protein degradation represents a revolutionary therapeutic approach and is rapidly gaining momentum in drug development. Unlike traditional small-molecule therapeutics that often modulate or ...

Thoughts

Getting to grips with validity at the UPC

Users of the patent system in Europe need to engage with how the Unified Patent Court (UPC) handles validity. Validity at the UPC matters because of the court’s popularity. About 900 first instance c...

Analysis

UK and European life sciences investment landscape: Financial trends and strategic IP considerations

The UK and European life sciences sectors have undergone significant shifts over the past two years, reflecting not just the natural volatility of this high-risk, high-reward industry, but also the ch...

Thoughts

Using in silico data to support patentability at the EPO: A guide for biotech stakeholders

Recent advancements mean that data generated by computational modelling are providing efficient and cost-effective alternatives to traditional laboratory research. This series explores the implication...

Thoughts

In silico data at the EPO: Sufficiency of disclosure for biotech inventions

The use of in silico data to supplement experimental evidence is on the rise. In the absence of clear EPO guidance about how such data will be assessed for sufficiency, this article explores how stake...

Thoughts

EPO oppositions: a renewed strategic relevance in the UPC era

Think the UPC replaced the need for EPO oppositions? Think again. In this article, we unpack why oppositions are still central to smart patent strategy in Europe.

Thoughts

Pharmaceutical NCEs: 5 ways to maximise protection in Europe

A small molecule pharmaceutical patent portfolio typically begins with an application directed to a new chemical entity (NCE). It’s the first ‘flag in the sand’ and getting this application right is c...

News

BREAKING NEWS – finally, a referral on description amendments

In G1/25, an EPO Board of Appeal has asked the Enlarged Board of Appeal (EBA) to consider whether it is really necessary for the description of a European patent or application to be amended to remove...

Let us keep you up to date. If you’d like to receive communications from us, ranging from breaking news to technical updates, thought leadership to event invitations, please let us know.

Connect with us